Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 12/20 | 0.81 |
| ▸ | F2 | P00734 | 1/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.60 |
| ▸ | PREP | P48147 | 1/20 | 0.59 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649860 | 0.99 | BDKRB2 (0.83) | BDKRB2F2OPRD1PREPMRGPRX2 | |
| SCHEMBL150645 | 0.99 | BDKRB2 (0.83) | BDKRB2F2OPRD1PREPMRGPRX2 | |
| SCHEMBL29930311 | 0.95 | BDKRB2 (0.76) | BDKRB2F2OPRD1 | |
| SCHEMBL29404860 | 0.93 | BDKRB2 (0.79) | BDKRB2F2OPRD1PREPMRGPRX2 | |
| SCHEMBL29484957 | 0.93 | BDKRB2 (0.79) | BDKRB2F2OPRD1PREPMRGPRX2 | |
| Bradykinin SCHEMBL3047797 | 0.93 | BDKRB2 (0.82) | BDKRB2F2OPRD1PREPMRGPRX2 | |
| Bradykinin SCHEMBL29530927 | 0.91 | BDKRB2 (0.79) | BDKRB2F2OPRD1PREPMRGPRX2 | |
| SCHEMBL20298701 | 0.91 | BDKRB2 (0.75) | BDKRB2F2OPRD1PREP | |
| SCHEMBL31289571 | 0.91 | BDKRB2 (0.66) | BDKRB2F2OPRD1 | |
| SCHEMBL30672603 | 0.91 | BDKRB2 (0.66) | BDKRB2F2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | SANOFI (FR) | 2026-02-24 | — | — | US | claimed |
| US-20230399388-A1 | METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN | SANOFI (FR) | 2023-12-14 | — | — | US | claimed |
| US-20230184786-A1 | Methods of Detecting and Treating Immune Responses Associated with Viral Infection | FORSYTH DENTAL INFIRMARY FOR CHILDREN, d/b/a THE FORSYTH INSTITUTE | 2023-06-15 | — | — | US | claimed |
| EP-4192843-A1 | PEPTIDES ABLE TO BIND ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) AND MEDICAL USES THEREOF | Ospedale Pediatrico Bambino Gesù (IT) | 2023-06-14 | — | — | EP | claimed |
| EP-4105658-A1 | IMPROVED BIOASSAY METHOD | Kashiv Biosciences, LLC (US) | 2022-12-21 | — | — | EP | claimed |
| US-20220317111-A1 | BIOASSAY METHOD | AMNEAL PHARMACEUTICALS LLC | 2022-10-06 | — | — | US | claimed |
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | SANOFI (FR) | 2026-02-24 | — | — | US | disclosed |
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | SANOFI (FR) | 2026-02-24 | — | — | US | disclosed |
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | SANOFI (FR) | 2026-02-24 | — | — | US | disclosed |
| US-12427209-B2 | Dual mode 18F-labelled theranostic compounds and uses thereof | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-09-30 | — | — | US | disclosed |
| CN-113773385-B | Antibodies to bradykinin B1 receptor ligands | 赛诺菲 | 2025-09-12 | — | — | CN | disclosed |
| CN-120441698-A | Antibodies to bradykinin B1 receptor ligands | 赛诺菲 | 2025-08-08 | — | — | CN | disclosed |
| US-20250241600-A1 | MULTI-DISEASE PATIENT MANAGEMENT | CARDIAC PACEMAKERS INC (US) | 2025-07-31 | — | — | US | disclosed |
| EP-3558960-B1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | Bayer Pharma AG (DE) | 2022-01-05 | — | — | EP | disclosed |
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| EP-3558972-A1 | TETRAZOLE CONTAINING COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558960-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-20190177279-A1 | CARBOXYLIC ACID AROMATIC 1,2-CYCLOPROPYLAMIDES | Bayer Pharma AG (DE) | 2019-06-13 | — | — | US | disclosed |
| WO-2018114786-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018114783-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427209-B2 | Dual mode 18F-labelled theranostic compounds and uses thereof | TFRC, SLC39A3, SLC39A14 | BDKRB2 2974/4885F2 2281/4885OPRD1 4276/4885 |
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | TSLP, IL5, TRPA1 | BDKRB2 297/4885F2 329/4885OPRD1 882/4885 |
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | BDKRB2, KLKB1, BDKRB1 | BDKRB2 1/4885F2 155/4885OPRD1 819/4885 |
| US-20190177279-A1 | CARBOXYLIC ACID AROMATIC 1,2-CYCLOPROPYLAMIDES | PAH, DDC, RIMKLA | BDKRB2 1156/4885F2 2114/4885OPRD1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.